boost anti-viral immunity after T-cell depleted HSCT
Проводит Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Страница компанииSafety and Efficacy Study of an Ex-vivo Antigen-primed Donor Memory Lymphocyte Infusion for the Enhancement of Immunity to Viral Infections Among Recipients of Allogeneic Hematopoietic Stem Cell Transplantation on the Platform of Selective Immunomagnetic Depletion of T-lymphocytes
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05066958/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Совмещённое исследование фаз Фаза I–II: Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного. Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: 1 мес. — 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 20 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Ожидаемая продолжительность жизнине меньше 4 нед.
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 7
Критерии включения
- Informed consent signed by the patient (ages 14 to 18) and / or his legal representative (ages 0 to 18).
- The patient has an indication for allogeneic transplantation of hematopoietic stem cells established in accordance with the current regulatory framework
- Planned HSCT selective immunomagnetic depletion of alpha/betta T lymphocytes
- Karnovsky or Lansky index more than 50%
- Life expectancy at least 4 weeks
- Heart function: ejection fraction of at least 40%
- Consent to continue follow-up for 5 years
Критерии невключения
- Acute viral hepatitis or acute HIV infection
- Hypoxemia with SaO2 <90%
- Bilirubin> 3 norms
- Creatinine> 3 norms
- Pregnancy and lactation
- Severe uncontrolled infection
- Severe (>?) pathology of the central nervous system (epilepsy, dementia, organic damage to the central nervous system, psychosis)
Источник: ClinicalTrials.gov, NCT05066958 · запись обновлена в реестре 4 октября 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (4), вторичных — 4
- acute Graft Versus Host Disease — 100 days after HSCT
- The proportion of patients with detectable T-cell response (IFNgamma ELISPOT) to CMV — after HSCT by day + 30 and by day + 180
- The proportion of patients with detectable T-cell response (IFNgamma ELISPOT) to ADV — after HSCT by day + 30 and by day + 180
- The proportion of patients with detectable T-cell response (IFNgamma ELISPOT) to EBV — after HSCT by day + 30 and by day + 180
Цель исследования
HSCT from an allogeneic donor is the standard therapy for high-risk hematopoietic malignancies and a wide range of severe non-malignant diseases of the blood and immune system. The possibility of performing HSCT was significantly limited by the availability of donors compatible with the MHC system. However, modern ex-vivo and in vivo technologies for depletion of T lymphocytes have made it possible to improve the outcomes of HSCT from partially compatible related (haploidentical) donors. In representative groups, it was shown that the success of HSCT from haploidentical donors is not inferior to standard procedures of HSCT from HLA-compatible unrelated donors. HSCT from haploidentical donors in children associated with the deficit of the adaptive immune response, which persists up to 6 months after HSCT and can be an increased risk of death of the patient from opportunistic infections. To solve this problem, the method of infusion of low doses of donor memory T lymphocytes was introduced. This technology is based on the possibility of adoptive transfer of memory immune response to key viral pathogens from donor to recipient. Such infusions have been shown to be safe and to accelerate the recovery of the pathogen-specific immune response. The expansion of virus-specific T lymphocytes in the recipient's body depends on exposure to the relevant antigen in vivo. Thus, in the absence of contact with the viral antigen, the adoptive transfer of memory T lymphocytes is not accompanied in vivo by the expansion of virus-specific lymphocytes and does not form a circulating pool of memory T lymphocytes, that can protect the patient from infections. Therefore the investigators assume that ex-vivo priming of donor memory lymphocytes with relevant antigens can provide optimal antigenic stimulation and may solve the problem of restoring immunological reactivity in the early stages after HSCT. Technically ex-vivo primed memory T lymphocytes will be generated by short incubation of CD45RA-depleted fraction of the graft (a product of T lymphocyte depletion) with a pool of GMP-quality peptides representing a number of key proteins of the viral pathogens. The following are proposed as targeted antigens: CMV pp65, EBV EBNA-1, EBV LMP12A, Adeno AdV5 Hexon, BKV LT, BKV VP1. An infusion of donor memory lymphocytes will be performed on the day +1 after transplantation. Parameters of the assessment will be safety and efficacy (immune response by day 60 and stability (responses by day 180).
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05066958 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.